Gold-standard Evidence and Best Practice Guidance for Menstrual Cycle-Informed Clinical Care: an Overview for Clinicians.

OBJECTIVES:To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle-related processes-particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)-into psychological assessment, formulation and treatment. DESIGN:Narrative, clinically oriented review. METHODS:We integrated findings from experimental, longitudinal and clinical studies on menstrual cycle physiology, hormone sensitivity, PMDD and PME, with a focus on evidence relevant to psychological practice. Emphasis was placed on gold-standard methodologies (e.g., prospective symptom assessment, biologically anchored cycle phase determination) and on translational relevance for clinical decision-making. RESULTS:A substantial minority of naturally cycling individuals show sensitivity to normative hormonal fluctuations, resulting in clinically significant distress or impairment. PMDD affects approximately 3-8% of menstruating individuals and is characterissed by severe, luteal-phase-specific symptoms and elevated suicidality risk. PME appears even more prevalent, affecting up to 50-60% of individuals with mood disorders. Despite this, menstrual cycle-related symptom patterns are rarely assessed or incorporated into routine care. The literature supports several key clinical strategies: (1) prospective daily symptom tracking across at least two menstrual cycles; (2) cycle-informed case formulations integrating timing and symptom expression; and (3) adaptation of evidence-based interventions to predictable cyclical patterns. Clinician-ready tools and case-based approaches facilitate implementation. CONCLUSIONS:The menstrual cycle represents a clinically meaningful yet underrecognized source of within-person variability in mental health. Integrating cycle-informed approaches into psychological care can enhance diagnostic precision, improve personalized formulations and optimize treatment outcomes for individuals affected by PMDD and PME.